The selection of commercially viable drug candidates and advancing their development
toward worldwide markets is a complex and challenging task that requires people with a broad
range of different qualifications and drug development know-how.


CMC specialist

Back to team

Bert studied biochemistry and got his Ph.D in pharmaceutical chemistry at University of California. Bert has held positions in companies with responsibilities for pharmaceutical development, manufacturing and controls., including Penederm (1990-1992), Neurobiological Technologies (1992-1998), Sugen (1999-2000), Amgen (2000-2004), Novacea (2005-2007), ChemoCentryx (2007-2013). Bert authored CMC section of more than 24 INDs and IMPDs. Bert has extensive experience in the development and manufacture of drug substance (small molecules and peptide) and dosage forms (parenteral, oral and topical). Bert  oversaw development and manufacturing programs at over 30 drug substance, drug product and analytical service contract laboratories.